Quarterly report · Q1
4574.TEDINET S100QQ1J
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥621m | 2022-01-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥155m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥3.4bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥19.7bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-5.59 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.26 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-40.13 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 54.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥241m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥124m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥5m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥215m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | ¥85m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-03-31 | −¥360m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥39m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥39m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥1.3bn |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥6m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥579m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥579m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥13m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-03-31 | ¥621m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-03-31 | ¥621m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-03-31 | −¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 339
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | -1692000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | -234000000 | JPY |
| Write downs of inventories | Prior1YTDDuration | 475000000 | JPY |
| Write downs of inventories | CurrentYTDDuration | -40000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 579000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 39000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 621000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 621000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 579000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 39000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 2000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 621000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 621000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 13000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | -1318000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | -6000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | -1311000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -360000000 | JPY |
| Operating income | Prior1YTDDuration | -1672000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 906000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 259000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 1000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1167000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1167000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 906000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 259000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 1000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1167000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 1167000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 215000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | -124000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | -5000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 85000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |